| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_390be8b40737dd62f57f366e17a9af5d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2007-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d0fe69714b9bf68f885d2a2d4a805ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75bf4f75b817a65f9edede97298daf9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed8dc48dc3333b3dcec5bb59a46b52cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29250e9b3dc87204935d5612f21601ff |
| publicationDate |
2008-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2663521-A1 |
| titleOfInvention |
Combinatorial therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
| abstract |
Described are uses of an agent that reduces B7-H1 interaction with PD-I, and particularly monoclonal antibodies that bind to B7-H1 and interfere with B7-H1 interaction with PD-I in combination with a vaccine to provide synergistic effects. The application provides methods of treatment and vaccination based on the combination of these compounds on T cell responses. |
| priorityDate |
2006-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |